COVID-19 Drug Study for Out-Patient Care
This study is closed to recruitment.
Phase 2/3 of RHB-107 (Upamostat), a Serine Protease Inhibitor or Placebo for Treatment of COVID-19 Disease
HEALTHY PARTICIPANTS: No
CONDITION: COVID-19, Coronavirus
Purpose of the Study
The purpose of this study is to test the safety of the study drug RHB-107, also referred to as Upamostat, in two different doses to see if it can help people with early COVID-19. Participants in this study will receive either a high or low dosage of Upamostat and/or placebo and will take it by mouth once per day for 14 days.